At Tango, we foster an environment where our differences are recognized and celebrated. Three associates – Simon Liang, Kat Finley, M.Ed and Suleman Hussain, Ph.D. – curated activities throughout June to celebrate #PrideMonth including a fun and creative Pride-themed Jeopardy event. The team also hosted a special lunch where associates enjoyed barbeque from Sweet Cheeks Q, a local LGBTQ+ owned restaurant, as they listened to Joseph Vogel, MBA of OUTbio Boston on the history of the non-profit LGBTQ+ professional biotech group as well as diversity, equity and inclusion in the industry and why it matters. This month reflects our commitment to an equitable community where associates can bring their authentic selves to work every day.
Tango Therapeutics
Biotechnology Research
Boston, Massachusetts 18,775 followers
Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medicines.
About us
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
- Website
-
https://www.tangotx.com/
External link for Tango Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 2017
- Specialties
- cancer, pharmaceutical research, functional genomics, drug discovery, and synthetic lethality
Locations
-
Primary
201 Brookline Ave
Suite 901
Boston, Massachusetts 02215, US
Employees at Tango Therapeutics
Updates
-
This morning, we announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines’ daraxonrasib or zoldonrasib in patients with RAS-mutant MTAP-deleted pancreatic or lung cancer. Read the press release here: https://lnkd.in/esizx9qn
-
-
Seventeen Tango associates hit the water of the Charles River to compete in the 46th Boston Hong Kong Dragon Boat Festival. Led by team captain Ashley Bui, CPA for the second year in a row, Team Tango demonstrated our values of courage, spirit and resilience, competing in six races over two days and for many, rowing for the first time! The team had an amazing performance and were able to take part in a cultural tradition celebrated worldwide and meaningful to many associates at Tango. Congrats to our rowers: Alvaro Amor, Arpita Mohapatra, Ben-Oni Jean-Pierre, Binzhang Shen, Dalton Riikonen, Daniella Beckman, Douglas Williams, MBA, Hana McMurtray, Hongxiang Z, Kasia Handing, Kat Finley, M.Ed, Katherine L., Peter Murphy, Ruolan Li, Simon Liang and Vivian Du.
-
Join us this afternoon as Barbara Weber, M.D., President and CEO, participates in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. Webcast and replay available here: https://lnkd.in/eMGwe8_V
-
-
Tango Therapeutics reposted this
Excited to be speaking at the Gordon Research Conference on Synthetic Lethality Approaches in Cancer this upcoming July! Looking forward to great discussions among old friends and new. https://lnkd.in/egAYqsBh
-
-
Tango Therapeutics reposted this
Thank you Drug Hunter for highlighting the recent disclosure of TNG961, Tango's first-in-class oral molecular glue degrader of HBS1L
HBS1L: A Hot Synthetic Lethality Target with a Molecular Glue Degrader from Tango Therapeutics | https://lnkd.in/g9uYfh8C Two back-to-back Nature papers from AbbVie and the Broad Institute of MIT and Harvard have spotlighted HBS1L/PELO as a compelling synthetic lethal partner in SKI-deficient tumors—particularly those with FOCAD deletions on chromosome 9p21.3. Tango Therapeutics independently disclosed a first-in-class molecular glue degrader (TNG961) targeting HBS1L, showing selective tumor regression in FOCAD-null xenograft models. This article highlights how the HBS1L/PELO complex functions as a key ribosomal rescue mechanism within the mRNA quality control machinery, and why FOCAD-deficient cancers—due to destabilization of the SKI complex—become highly dependent on HBS1L for survival. We also highlight Tango’s development of TNG961, an oral molecular glue degrader that demonstrates high selectivity for killing FOCAD-deficient cells and drives tumor regression in preclinical models. Read more to learn why this synthetic lethality story is worth watching: https://lnkd.in/g9uYfh8C
-
-
“CRISPR screens identify POLB as a synthetic lethal enhancer of PARP inhibition exclusively in BRCA-mutated tumors” was recently published in Molecular Cancer Therapeutics. Although we stopped the development of POLB, this research highlights the potential of POLB as a promising therapeutic target for enhancing antitumor responses to PARP inhibitors in homologous recombination-deficient cancers. By utilizing our CRISPR target discovery screening platform, we identified POLB as a gene that acts selectively and synergistically with PARP inhibitors in BRCA1/2 mutated cancers. These findings suggest that POLB knockout, in combination with PARP inhibition, leads to increased single and double strand DNA breaks, cell cycle arrest, and apoptosis, resulting in profound tumor regression in animal studies. This work underscores the importance of exploring new therapeutic agents targeting POLB to overcome acquired resistance and improve disease free outcomes for patients. Read the full manuscript here: https://lnkd.in/eC94-XZV
-
Tango Therapeutics reposted this
I am excited to be speaking at the 2nd Annual Hit ID Summit this coming fall! It will be great to learn about new methods and technologies being used to identify and characterize hit molecules for drug discovery! See the full Event Guide for more information here: https://ter.li/x7j19z
-
-
Last week we came together for our annual full-day Community Service event, this year at Cradles to Crayons Massachusetts. It was an inspiring day of teamwork to make a difference in children’s lives. In just one day we: 📦 Processed and sorted 29 bins of donations 👖 Filled 167 totes of clothing 👚 Assembled 375 outfit packs 👠 Sorted and cleaned 500 pairs of shoes 📰 Fulfilled 27 partner orders Together, we provided local children and teens with the everyday essentials they need for a safe and healthy childhood. #endclothinginsecurity
-
Tango Therapeutics reposted this
Very excited to be speaking at the 54th Organic Process Research and Development Conference this coming fall! Looking forward to insightful discussions and reconnecting with colleagues across the industry! https://lnkd.in/eTrVzVMj #OPRDEU2025
-